(AZN) AstraZeneca - Ratings and Ratios
Oncology, Cardiovascular, Respiratory, Rare-Disease, Vaccines
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.68% |
| Yield on Cost 5y | 3.42% |
| Yield CAGR 5y | 1.48% |
| Payout Consistency | 92.5% |
| Payout Ratio | 35.9% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Value at Risk 5%th | 36.0% |
| Relative Tail Risk | -4.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.28 |
| Alpha | 31.37 |
| CAGR/Max DD | 0.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.524 |
| Beta | 0.395 |
| Beta Downside | 0.528 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.87% |
| Mean DD | 9.92% |
| Median DD | 9.79% |
Description: AZN AstraZeneca December 01, 2025
AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical firm headquartered in Cambridge, UK, that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease therapeutic areas. Its product roster includes blockbuster oncology agents such as Tagrisso and Imfinzi, metabolic drugs like Farxiga, and respiratory treatments such as Symbicort, sold through a network of distributors and local offices in the United Kingdom, United States, Europe, and Asia. The company has strategic partnerships with Tempus (oncology AI), IonQ (quantum-accelerated chemistry), CSPC (oral candidate discovery), and Revna Biosciences (lung-cancer therapy).
In FY 2023, AstraZeneca reported revenue of approximately $44.5 billion, driven by a 5% year-over-year increase in oncology sales and double-digit growth in its cardiovascular-renal portfolio, reflecting strong demand for Tagrisso and Farxiga. The firm’s pipeline features over 30 late-stage candidates, with Tagrisso-plus and Imfinzi-plus expected to sustain high-margin growth amid a sector-wide shift toward targeted cancer therapies. Macro-level drivers include an aging global population, rising prevalence of chronic diseases, and continued pressure on drug pricing, which together shape the company’s pricing strategy and R&D allocation.
For a deeper dive into AZN’s valuation metrics and forward-looking cash-flow projections, the ValueRay platform offers a concise analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (9.40b TTM) > 0 and > 6% of Revenue (6% = 3.49b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 3.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.08% (prev -3.46%; Δ -3.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 15.14b > Net Income 9.40b (YES >=105%, WARN >=100%) |
| Net Debt (24.52b) to EBITDA (17.94b) ratio: 1.37 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.12b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 82.28% (prev 80.88%; Δ 1.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.99% (prev 48.80%; Δ 4.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.30 (EBITDA TTM 17.94b / Interest Expense TTM 1.57b) >= 6 (WARN >= 3) |
Altman Z'' 0.96
| (A) -0.04 = (Total Current Assets 29.94b - Total Current Liabilities 34.05b) / Total Assets 114.46b |
| (B) 0.07 = Retained Earnings (Balance) 8.21b / Total Assets 114.46b |
| (C) 0.12 = EBIT TTM 13.01b / Avg Total Assets 109.69b |
| (D) 0.16 = Book Value of Equity 10.64b / Total Liabilities 68.48b |
| Total Rating: 0.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.75
| 1. Piotroski 8.0pt |
| 2. FCF Yield 3.61% |
| 3. FCF Margin 19.18% |
| 4. Debt/Equity 0.71 |
| 5. Debt/Ebitda 1.37 |
| 6. ROIC - WACC (= 7.09)% |
| 7. RoE 21.80% |
| 8. Rev. Trend 87.65% |
| 9. EPS Trend 48.85% |
What is the price of AZN shares?
Over the past week, the price has changed by +1.70%, over one month by +2.18%, over three months by +17.78% and over the past year by +40.81%.
Is AZN a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99 | 8.3% |
| Analysts Target Price | 99 | 8.3% |
| ValueRay Target Price | 107.3 | 17.4% |
AZN Fundamental Data Overview December 17, 2025
P/E Trailing = 30.4186
P/E Forward = 17.4216
P/S = 4.8839
P/B = 6.0696
P/EG = 1.0311
Beta = 0.168
Revenue TTM = 58.13b USD
EBIT TTM = 13.01b USD
EBITDA TTM = 17.94b USD
Long Term Debt = 24.70b USD (from longTermDebt, last quarter)
Short Term Debt = 6.58b USD (from shortTermDebt, last quarter)
Debt = 32.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.52b USD (from netDebt column, last quarter)
Enterprise Value = 308.37b USD (283.89b + Debt 32.66b - CCE 8.18b)
Interest Coverage Ratio = 8.30 (Ebit TTM 13.01b / Interest Expense TTM 1.57b)
FCF Yield = 3.61% (FCF TTM 11.15b / Enterprise Value 308.37b)
FCF Margin = 19.18% (FCF TTM 11.15b / Revenue TTM 58.13b)
Net Margin = 16.17% (Net Income TTM 9.40b / Revenue TTM 58.13b)
Gross Margin = 82.28% ((Revenue TTM 58.13b - Cost of Revenue TTM 10.30b) / Revenue TTM)
Gross Margin QoQ = 81.16% (prev 82.89%)
Tobins Q-Ratio = 2.69 (Enterprise Value 308.37b / Total Assets 114.46b)
Interest Expense / Debt = 1.07% (Interest Expense 349.0m / Debt 32.66b)
Taxrate = 21.86% (709.0m / 3.24b)
NOPAT = 10.16b (EBIT 13.01b * (1 - 21.86%))
Current Ratio = 0.88 (Total Current Assets 29.94b / Total Current Liabilities 34.05b)
Debt / Equity = 0.71 (Debt 32.66b / totalStockholderEquity, last quarter 45.89b)
Debt / EBITDA = 1.37 (Net Debt 24.52b / EBITDA 17.94b)
Debt / FCF = 2.20 (Net Debt 24.52b / FCF TTM 11.15b)
Total Stockholder Equity = 43.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.21% (Net Income 9.40b / Total Assets 114.46b)
RoE = 21.80% (Net Income TTM 9.40b / Total Stockholder Equity 43.11b)
RoCE = 19.18% (EBIT 13.01b / Capital Employed (Equity 43.11b + L.T.Debt 24.70b))
RoIC = 13.88% (NOPAT 10.16b / Invested Capital 73.23b)
WACC = 6.79% (E(283.89b)/V(316.55b) * Re(7.47%) + D(32.66b)/V(316.55b) * Rd(1.07%) * (1-Tc(0.22)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 79.95% ; FCFE base≈9.39b ; Y1≈10.59b ; Y5≈14.31b
Fair Price DCF = 79.93 (DCF Value 247.82b / Shares Outstanding 3.10b; 5y FCF grow 14.89% → 3.0% )
EPS Correlation: 48.85 | EPS CAGR: 9.73% | SUE: 0.44 | # QB: 0
Revenue Correlation: 87.65 | Revenue CAGR: 6.46% | SUE: 1.11 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.26 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=5.15 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+12.1% | Growth Revenue=+6.4%
Additional Sources for AZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle